Brain and Nerves

The purpose of this study is to explore the use of bright light therapy as maintenance treatment for depression to determine if it is

The purpose of this study is to learn about biomarkers (biological features such as proteins, genes, and brain images that indicate the state of a disease in a person), and how they can help predict treatment outcomes in patients with clinical depression. 

The  purpose of this study is to evaluate the safety and efficacy of the drug ravulizumab for the treatment of participants with generalized myasthenia gravis.

The purpose of this study is to assess the efficacy and safety of CNM-Au8 as a remyelinating therapy in patients with stable relapsing-remitting multiple
sclerosis (RMS).

The purpose of this study is to assess the safety and tolerability of valbenazine for the treatment of chorea associated with Huntington's Disease.

The purpose of this study is to explore certain aspects of the blood and brain to determine how a person may recover from COVID-19. In addition, this study will examine how the different aspects of COVID-19 may affect how a person thinks or feels. 

The ESCAPE-NA-1 study is designed to determine the safety and efficacy of the neuroprotectant, NA-1, in reducing global disability in subjects with major acute ischemic stroke (AIS) who are selected for endovascular revascularization.

This is a prospective, multicenter, open-label, single-arm, phase 3b study which evaluates effectiveness and safety of ocrelizumab in participants with early stage RRMS. The study will consist of an open-label treatment period of 192 weeks and follow-up period of at least 48 weeks.

There is a new theory that Parkinson's disease may start in the gut, but research is limited.  The purpose of this study is to better understand the association between Parkinson's disease and the bacteria and fungi living in the gut and nose.

Recruitment poster

The purpose of this study is to demonstrate the superiority of MD1003 over placebo in the disability of patients suffering from progressive multiple sclerosis and especially those with gait impairment

MS is a disabling neurological disease with a highly variable clinical course including acute disability (relapses when symptoms appear or worsen) and disease progression (steady accumulation of disability in the absence of relapses). There is currently no approved treatment for progressive MS. A principal pathology of MS is the destruction of myelin, which surrounds nerves to speed up signal conduction. We have developed a magnetic resonance imaging technique that provides quantitative measurements of myelin.

The purpose of this study is to provide confirmatory evidence of the safety and efficacy of two Dysport® (AbobotulinumtoxinA) doses (600 units [U] and 800 U), compared to placebo in reducing urinary incontinence (UI) in adult subjects treated for neurogenic detrusor overactivity (NDO) due to spinal cord injury (SCI) or multiple sclerosis (MS).

To compare the efficacy and safety of ofatumumab administered subcutaneously (sc) every 4 weeks versus teriflunomide administered orally once daily in patients with relapsing multiple sclerosis.